Page last updated: 2024-10-25

cl 387785 and Polycystic Kidney Diseases

cl 387785 has been researched along with Polycystic Kidney Diseases in 4 studies

CL 387785: structure in first source
N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.

Polycystic Kidney Diseases: Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.

Research Excerpts

ExcerptRelevanceReference
"Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor."1.31Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. ( Avner, ED; Chen, Y; Frost, P; Nakanishi, K; Sweeney, WE, 2000)
"Recessively transmitted polycystic kidney disease (PKD) in many murine models is characterized by the initial formation of proximal tubular cysts (stage 1), followed by growth and enlargement of renal collecting tubule (CT) cysts (stage 2)."1.30In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor. ( Avner, ED; Frost, P; Futey, L; Sweeney, WE, 1999)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Torres, VE1
Sweeney, WE3
Wang, X1
Qian, Q1
Harris, PC1
Frost, P3
Avner, ED3
Futey, L1
Chen, Y1
Nakanishi, K1
Marfella-Scivittaro, C1
QuiƱones, A1
Orellana, SA1

Other Studies

4 other studies available for cl 387785 and Polycystic Kidney Diseases

ArticleYear
EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats.
    Kidney international, 2003, Volume: 64, Issue:5

    Topics: Animals; Disease Models, Animal; ErbB Receptors; Gastric Lavage; Injections, Intraperitoneal; Male;

2003
In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor.
    Kidney international, 1999, Volume: 56, Issue:2

    Topics: Animals; Cell Division; Cell Survival; Disease Models, Animal; Enzyme Inhibitors; Epidermal Growth F

1999
Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor.
    Kidney international, 2000, Volume: 57, Issue:1

    Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Mice;

2000
cAMP-dependent protein kinase and proliferation differ in normal and polycystic kidney epithelia.
    American journal of physiology. Cell physiology, 2002, Volume: 282, Issue:4

    Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Cell Division; Cells, Cultured; Cyclic AMP; Cyclic

2002